DFV890
A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 80 patients (estimated)
- Sponsors
- Novartis
- Tags
- NLRP3 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1752
- NCT Identifier
- NCT05552469
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.